Table 1.
Proportion of sample use for newer and established drugs in the USA, 2009–2013
| Approval | Generic approval | New use, sample any (%)a | Continued use, sample any (%)a | |
|---|---|---|---|---|
| Antidiabetic drugs | ||||
| Sitagliptin | 2006 | – | 44.7 | 17.0 |
| Exenatide | 2005 | – | 38.1 | 9.8 |
| Pioglitazone | 1999 | 2012 | 28.5 | 12.4 |
| Metformin | 1995 | 2002 | 3.6 | 1.2 |
| Glipizide | 1984 | 1995 | <3.0b | <3.0b |
| Antihyperlipidemic drugs | ||||
| Rosuvastatin | 2003 | – | 48.5 | 23.9 |
| Atorvastatin | 1996 | 2011 | 22.9 | 9.1 |
| Simvastatin | 1991 | 2006 | 1.2 | 1.1 |
| Pravastatin | 1991 | 2006 | <3.0b | <3.0b |
| Antihypertensive drugs | ||||
| Losartan | 1995 | 2010 | 11.8 | 2.6 |
| Amlodipine | 1992 | 2005 | 1.3 | 0.9 |
| Enalapril | 1985 | 2001 | >3.0b | <3.0b |
| Anticoagulants | ||||
| Dabigatran | 2010 | – | 43.5 | 22.7 |
| Warfarin | 1954 | 1997 | <3.0b | <3.0b |
| Antibiotics, oral | ||||
| Moxifloxacin | 1999 | 2014 | 24.3 | >3.0b |
| Levofloxacin | 1996 | 2011 | 8.1 | >3.0b |
| Ciprofloxacin | 1987 | 2004 | 3.7 | 5.3 |
| Antibiotics, ophthalmic | ||||
| Moxifloxacin | 2003 | – | 14.0 | >3.0b |
| Levofloxacin | 2000 | 2011 | 40.1 | >3.0b |
| Ciprofloxacin | 1990 | 2004 | 7.4 | >3.0b |
| Drugs for ADHD | ||||
| Atomoxetine | 2002 | – | 27.7 | 14.4 |
| Methylphenidate | 1955 | 1997 | <3.0b | 0.7 |
| Oral contraceptives containing | ||||
| Drospirenone/EE | 2001 | 2013 | 59.4 | 38.1 |
| Norgestimate/EE | 1992 | 2011 | 20.3 | 11.5 |
| Levonorgestrel/EE | 1982 | 2011 | 20.9 | 12.4 |
| Norethindrone/EE/fe | 1976 | 2011 | 75.3 | 55.8 |
Data source: Encuity Research, LLC, TreatmentAnswersTM Audit. Extracted June 2014
ADHD attention-deflcit/hyperactivity disorder. EE ethinyl estradiol, fe ferrous fumarate
a
Proportion of visits during which a sample was provided among visits with issued prescription and/or sample of drug of interest
b
Based on fewer than 100,000 projected counts